Diagnostic details of AML patients with DDX18 nonsynonymous sequence variants
| . | Age, y . | Sequence variant . | M/F . | Diagnosis/WHO classification . | Cytogenetics . | Molecular characteristics . | BLAST cell immunophenotype . |
|---|---|---|---|---|---|---|---|
| PT33 | 81 | C183Y and C371I | M | Relapsed AML M6 | 46XY | Not available | CD45+, CD13+, CD33+, CD34+, CD117+ |
| PT40 | 20 | C671I | M | De novo AML | 46XY | Not available | CD34+, CD13+, CD33+, CD7+ |
| MSK1 | 72 | E76del | F | AML evolved from MDS | 46XX | Wild type (TET2, ASXL1, IDH2, FLT3, NPM1, CEBPA, p53) R132C IDH1 | Not available |
| . | Age, y . | Sequence variant . | M/F . | Diagnosis/WHO classification . | Cytogenetics . | Molecular characteristics . | BLAST cell immunophenotype . |
|---|---|---|---|---|---|---|---|
| PT33 | 81 | C183Y and C371I | M | Relapsed AML M6 | 46XY | Not available | CD45+, CD13+, CD33+, CD34+, CD117+ |
| PT40 | 20 | C671I | M | De novo AML | 46XY | Not available | CD34+, CD13+, CD33+, CD7+ |
| MSK1 | 72 | E76del | F | AML evolved from MDS | 46XX | Wild type (TET2, ASXL1, IDH2, FLT3, NPM1, CEBPA, p53) R132C IDH1 | Not available |